238 related articles for article (PubMed ID: 26989470)
1. Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?
Savic LJ; Chapiro J; Duwe G; Geschwind JF
Hepat Oncol; 2016 Jan; 3(1):19-28. PubMed ID: 26989470
[TBL] [Abstract][Full Text] [Related]
2. Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities.
Rossi SM; Murray T; McDonough L; Kelly H
Expert Opin Drug Deliv; 2021 May; 18(5):607-623. PubMed ID: 33253052
[No Abstract] [Full Text] [Related]
3. An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma.
Bimonte S; Barbieri A; Palaia R; Leongito M; Albino V; Piccirillo M; Arra C; Izzo F
Infect Agent Cancer; 2015; 10():9. PubMed ID: 25755676
[TBL] [Abstract][Full Text] [Related]
4. Locoregional and systemic therapy for hepatocellular carcinoma.
Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.
Savic LJ; Chapiro J; Geschwind JH
Hepatobiliary Surg Nutr; 2017 Feb; 6(1):7-21. PubMed ID: 28261591
[TBL] [Abstract][Full Text] [Related]
6. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies.
Lencioni R
Oncology; 2010 Jul; 78 Suppl 1():107-12. PubMed ID: 20616592
[TBL] [Abstract][Full Text] [Related]
7. Loco-regional cancer drug therapy: present approaches and rapidly reversible hydrophobization (RRH) of therapeutic agents as the future direction.
Budker VG; Monahan SD; Subbotin VM
Drug Discov Today; 2014 Dec; 19(12):1855-70. PubMed ID: 25173702
[TBL] [Abstract][Full Text] [Related]
8. Loco-regional treatment of hepatocellular carcinoma.
Lencioni R
Hepatology; 2010 Aug; 52(2):762-73. PubMed ID: 20564355
[TBL] [Abstract][Full Text] [Related]
9. Treatment modalities for hepatocellular carcinoma.
Hung H
Curr Cancer Drug Targets; 2005 Mar; 5(2):131-8. PubMed ID: 15810877
[TBL] [Abstract][Full Text] [Related]
10. Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during the COVID-19 pandemic.
How GY; Pua U
J Interv Med; 2022 Nov; 5(4):180-183. PubMed ID: 36532308
[TBL] [Abstract][Full Text] [Related]
11. Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma.
Wu TH; Wang YC; Cheng CH; Lee CF; Wu TJ; Chou HS; Chan KM; Lee WC
World J Gastrointest Surg; 2020 Jan; 12(1):17-27. PubMed ID: 31984121
[TBL] [Abstract][Full Text] [Related]
12. Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects.
Lencioni R; Crocetti L; De Simone P; Filipponi F
Transpl Int; 2010 Jul; 23(7):698-703. PubMed ID: 20492618
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
Hulin A; Stocco J; Bouattour M
Clin Pharmacokinet; 2019 Aug; 58(8):983-1014. PubMed ID: 31093928
[TBL] [Abstract][Full Text] [Related]
14. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
15. Surface Engineering of Nanoparticles for Targeted Delivery to Hepatocellular Carcinoma.
Lu J; Wang J; Ling D
Small; 2018 Feb; 14(5):. PubMed ID: 29251419
[TBL] [Abstract][Full Text] [Related]
16. Established and emerging therapies for hepatocellular carcinoma.
Cicinnati VR; Sotiropoulos GC; Beckebaum S
Minerva Med; 2010 Dec; 101(6):405-18. PubMed ID: 21196900
[TBL] [Abstract][Full Text] [Related]
17. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma: systemic therapies and future perspectives.
Mikhail S; Cosgrove D; Zeidan A
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1205-18. PubMed ID: 25199765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
